Sarcoidosis Lung
Conditions
Keywords
lymphoma, sarcoidosis
Brief summary
Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development
Detailed description
This is a prospective observational cohort study to be conducted in the Chest Diseases Department, Alexandria Main University Hospital. A total of 40 adult patients (≥16 years) with biopsy-proven sarcoidosis will be consecutively recruited between December 2024 and December 2025. All patients will be either newly starting or continuing immunosuppressive therapy for sarcoidosis. The treatment regimen-systemic corticosteroids, conventional steroid-sparing agents (methotrexate, azathioprine, or mycophenolate), or biologics (anti-TNF agents)-will be recorded but not altered by study design. Each patient will be followed prospectively for 12 months from enrollment.
Interventions
PROCEDURElymph node biopsy
sarcoidosis diagnosis by lymph node biopsy excisiona or bronchoscopic
Sponsors
Alexandria University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy
Exclusion criteria
Patients with a prior history of lymphoma or other active malignancy, HIV infection, or other primary immunodeficiency will be excluded. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome will be incident, biopsy-proven lymphoma during the 12-month follow-up. | 12 MONTHS | LYMPH NODE BIOPSY EITHER EXCISIONAL OR BRONCHOSCOPIC |
| lymphoma development | 12 months | lymph node biopsy excisional or bronchoscopic |
Countries
Egypt
Outcome results
None listed